Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek's two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne, and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI), and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily, tetracycline-derived compound designed for use in the treatment of acne and rosacea.